National Academies' Standing Committee on Emerging Infectious Diseases

National Academies' Standing Committee on Emerging Infectious Diseases
Name	National Academies' Standing Committee on Emerging Infectious Diseases
Type	Advisory committee
Established	20th century
Headquarters	Washington, D.C.
Parent organization	National Academies of Sciences, Engineering, and Medicine

National Academies' Standing Committee on Emerging Infectious Diseases The Standing Committee on Emerging Infectious Diseases is an advisory body convened under the aegis of the National Academies of Sciences, Engineering, and Medicine to address threats posed by novel pathogens, antimicrobial resistance, and zoonotic spillover. It interfaces with agencies such as the Centers for Disease Control and Prevention, the World Health Organization, the National Institutes of Health, and intergovernmental initiatives including the Global Health Security Agenda and the Coalition for Epidemic Preparedness Innovations. The committee synthesizes expertise drawn from institutions like Harvard University, Johns Hopkins University, University of Oxford, The Lancet, and public health agencies to produce consensus guidance for policymakers and practitioners.

History and Establishment

The committee traces its origins to earlier advisory panels convened after events such as the SARS outbreak of 2002–2004, the emergence of avian influenza concerns in the 1990s, and the Ebola virus epidemic in West Africa (2014–2016), responding to calls from stakeholders including the U.S. Department of Health and Human Services, the World Bank, and the Pan American Health Organization. Its formal charter was established to coordinate long-term scientific assessment, drawing on precedents like the Institute of Medicine reports on public health preparedness and the National Research Council reviews of biodefense. Founding membership included experts affiliated with Centers for Disease Control and Prevention, Food and Drug Administration, Wellcome Trust, and academic centers such as Massachusetts Institute of Technology and Stanford University.

Mandate and Objectives

The committee's mandate encompasses horizon scanning for emerging pathogens, evaluation of surveillance systems operated by bodies like the European Centre for Disease Prevention and Control and Africa Centres for Disease Control and Prevention, assessment of diagnostics and vaccine platforms developed by entities such as Moderna, Pfizer, and AstraZeneca, and recommendations for antimicrobial stewardship aligned with guidance from the World Organisation for Animal Health and United Nations Environment Programme. Objectives include informing strategic investment by institutions like the Bill & Melinda Gates Foundation, advising legislative bodies such as the United States Congress and the European Parliament, and supporting preparedness exercises conducted with partners including the Johns Hopkins Center for Health Security and the Clade X simulation lineage.

Membership and Organization

Membership typically comprises clinicians, epidemiologists, virologists, modelers, and ethicists drawn from universities such as Columbia University, University of California, San Francisco, Imperial College London, and research institutes like the Broad Institute and Pasteur Institute. Organizational structure includes a chair, co-chairs, topic-specific working groups, and liaisons from agencies including the Department of Defense and United States Agency for International Development. The committee collaborates with journal editors at Nature and Science and with professional societies such as the American Society for Microbiology and the Infectious Diseases Society of America to rapid-review evidence and convene workshops with stakeholders like Gavi, the Vaccine Alliance.

Key Activities and Reports

The committee issues consensus reports, technical memos, and workshop proceedings addressing subjects from pandemic influenza scenarios to pathogen genomics. Notable outputs have influenced guidance on diagnostics during the COVID-19 pandemic, evaluations of genomic surveillance best practices used by the COVID-19 Genomics UK Consortium, and recommendations on one-health approaches championed by the World Health Assembly. Reports often synthesize evidence from studies published in The New England Journal of Medicine, BMJ, and Cell, and recommend implementation pathways engaging funders such as the Wellcome Trust and the National Science Foundation.

Influence on Policy and Public Health Response

The committee's analyses have informed policy decisions by the U.S. Department of Health and Human Services, shaped operational strategies at the Centers for Disease Control and Prevention, and guided international responses coordinated by the World Health Organization and the United Nations. Its recommendations have been cited in legislative hearings before the United States Senate and used by ministries of health in countries including Brazil, India, and South Africa to structure surveillance investments and laboratory networks. The committee has also provided expert testimony and technical annexes for multilateral initiatives like the Global Fund to Fight AIDS, Tuberculosis and Malaria and the CEPI funding portfolio.

Controversies and Criticisms

Critics have challenged the committee on issues including perceived conflicts of interest when members have affiliations with pharmaceutical companies such as GlaxoSmithKline and Johnson & Johnson, transparency of deliberations compared with standards advocated by Transparency International, and the timeliness of recommendations during fast-moving events like the 2014–2016 Ebola epidemic and the COVID-19 pandemic. Some public health advocates and scholars from institutions like Harvard T.H. Chan School of Public Health and London School of Hygiene & Tropical Medicine have argued the committee underemphasized equity considerations highlighted by Médecins Sans Frontières and Oxfam in access to countermeasures.

Future Directions and Priorities

Future priorities include strengthening pathogen-agnostic surveillance systems with collaborations involving Illumina and academic consortia, integrating climate-linked risk assessments promoted by the Intergovernmental Panel on Climate Change and United Nations Framework Convention on Climate Change into spillover forecasting, and advancing policy frameworks for data sharing endorsed by World Health Assembly resolutions. The committee is expected to deepen partnerships with regional bodies such as the African Union and the Association of Southeast Asian Nations to bolster capacity-building and to advise on governance of dual-use research in coordination with agencies like the Biological Weapons Convention signatories and the Organisation for Economic Co-operation and Development.

Category:Public health organizations